Erickson v. Baxter Healthcare, Inc.

131 F. Supp. 2d 995, 2001 U.S. Dist. LEXIS 1575, 2001 WL 135709
CourtDistrict Court, N.D. Illinois
DecidedFebruary 9, 2001
Docket99 C 0426
StatusPublished
Cited by12 cases

This text of 131 F. Supp. 2d 995 (Erickson v. Baxter Healthcare, Inc.) is published on Counsel Stack Legal Research, covering District Court, N.D. Illinois primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Erickson v. Baxter Healthcare, Inc., 131 F. Supp. 2d 995, 2001 U.S. Dist. LEXIS 1575, 2001 WL 135709 (N.D. Ill. 2001).

Opinion

MEMORANDUM OPINION AND ORDER

BUCKLO, District Judge.

Walter Erickson was a hemophiliac who received intravenous transfusions of commercial blood factors manufactured by the defendants in this case. He died of AIDS and hepatitis in 1998. Ms. Erickson, his surviving spouse, claims that the factors were infected with hepatitis B and C and HIV. She brings a wrongful death and a survival action against the defendants. She moves to bar defendants experts from testifying about certain opinions on the ground that they are irrelevant, prejudicial, and do not meet the standards for expert testimony under Federal Rule of Evidence 702. I grant Ms. Erickson’s motion in part and deny it in part. 1

I.

When Mr. Erickson was eight years old, he was diagnosed with hemophilia, a hereditary illness that inhibits blood clotting and creates risks of uncontrolled bleeding. Hemophilia can be treated by a transfusion of clotting factors from human blood plasma. Mr. Erickson received intravenous factor concentrates beginning when he was a teenager. Mr. Erickson became infected with hepatitis B and C and HIV, and he died in 1998 of complications associated with AIDS and hepatitis.

Ms. Erickson alleges that commercial factor concentrates like the ones manufactured by the defendants present a high risk of hepatitis and HIV infection. Factor concentrates are processed from blood and plasma contributed from donors, many of whom are paid, and many of whom are at greater risk for dangerous viral infections than the rest of the population. Ms. Erickson claims that there were technologies in existence by 1981 to test for and eliminate the risk of hepatitis infection and that the defendants did not use these technologies. She also contends that the defendants were aware of the risk that a transmissible agent (later identified as HIV) was contaminating factor products and that they did nothing to warn hemophiliacs like Mr. Erickson of the risk of infection. Ms. Erickson challenges the opinions of several of the defendants’ experts.

II.

The amended Rule 702, governing the admissibility of expert testimony, now reads:

*999 If scientific, technical, or other specialized knowledge will assist the trier of fact to understand the evidence or to determine a fact in issue, a witness qualified as an expert by knowledge, skill, experience, training, or education, may testify thereto in the form of an opinion or otherwise, if (1) the testimony is based upon sufficient facts or data, (2) the testimony is the product of reliable principles and methods, and (3) the witness has applied the principles and methods reliably to the facts of the case.

This rule essentially codifies the principles enunciated in the line of cases following Daubert v. Merrell Dow Pharm. Inc., 509 U.S. 579, 113 S.Ct. 2786, 125 L.Ed.2d 469 (1993), requiring that expert testimony must be reliable to be admissible. What has been* added are three new “reliability” requirements: reliable data, reliable methodology, and reliable application of the methodology. Trial judges must act as “gatekeepers” to “ensure that any and all scientific testimony or evidence admitted is not only relevant, but reliable.” Daubert, 509 U.S. at 589, 113 S.Ct. 2786. The first step is to determine whether the testimony is “scientific knowledge” that has been subjected to the scientific method. Id. at 590, 113 S.Ct. 2786. Four factors bear on the reliability of expert testimony: (1) the testability of the hypothesis; (2) whether the theory or technique has been subject to peer review or publication; (3) the known or potential rate of error; and (4) whether the technique is generally accepted. Id. at 593-94, 113 S.Ct. 2786. The second step is to determine whether the expert’s testimony would be helpful; that is to say, whether it is sufficiently tied to the facts of the case to help the jury resolve some factual dispute. Id. at 591, 113 S.Ct. 2786. If an expert offers no support for an opinion, however, it is impossible to evaluate the testimony in terms of the factors laid out in Daubert so the testimony is excludable. See, e.g., Dukes v. Illinois Cent. R.R. Co., 934 F.Supp. 939, 949 (testimony did not meet Daubert standards where no support was given).

III.

Ms. Erickson offers the testimony of Dr. Mosley, a hematologist. The defendants have disclosed five experts to rebut the testimony of Dr. Mosley. Ms. Erickson has objected to specific opinions of each of the witnesses as unsupported, and she objects to testimony by any of the proffered experts about the likelihood that Mr. Erickson was infected with hepatitis by a needlestick or that his hepatitis was aggravated by alcohol abuse. I go through her objections expert by expert, but her objections to Dr. Holland’s testimony are addressed in the discussion of the other doctors’ testimony.

A. Dr. Kingsley

Ms. Erickson’s first objection is to Dr. Kingsley’s opinion that “chronic hepatitis B develops in only 5-10% of those who become infected.” Dr. Kingsley does not identify any source for his opinion or statistics. The defendants argue that “it is clear that Dr. Kingsley is relying upon his many years of experience in epidemiology-”

Although Rule 702 allows witnesses to be qualified on the basis of experience, and permits them to testify in the form of an opinions, see Walker v. Soo Line R. Co., 208 F.3d 581, 591 (7th Cir.2000), it does not permit experts to testify to any opinion based on general experience. Daubert clearly requires that opinions given under Rule 702 “pertain to ‘scientific knowledge,’ ” not “subjective belief or unsupported speculation.” 509 U.S. at 590, 113 S.Ct. 2786. Dr. Kingsley must point to some specific relevant experience that would allow me to determine that his statistical testimony is reliable. To allow doctors to testify about specific statistical or medical questions and base their testimony only on general experience would be to say that doctors are qualified experts on every medical subject merely because they wear white coats.

*1000 I am especially reluctant to consider Dr. Kingsley’s general medical background as a reliable source for statistical evidence in particular. Statistical evidence must have a specific source to be reliable; a number pulled out of the air is not “scientific knowledge.” Dr. Kingsley is barred from offering statistics on viral chronicity in his testimony. For the same reasons, Dr. Holland is also barred from testifying that evidence of primary HIV infection occurs in less than 20% of patients.

Second, Dr. Kingsley offers an opinion about the time of Mr. Erickson’s HIV infection. He disagreed with Dr. Mosley’s opinion that Mr. Erickson became infected in 1981 because the “symptoms of acute HIV illness [primary infection] are extremely broad and non-specific.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

SLATTERY v. MAIN LINE HEALTH, INC.
E.D. Pennsylvania, 2025
Korbe v. Manchester
D. Colorado, 2024
United States v. Rodriguez
125 F. Supp. 3d 1216 (D. New Mexico, 2015)
Richman v. Sheahan
415 F. Supp. 2d 929 (N.D. Illinois, 2006)
United States v. Richard Junior Frazier
387 F.3d 1244 (Eleventh Circuit, 2004)
Cloud v. Pfizer Inc.
198 F. Supp. 2d 1118 (D. Arizona, 2001)
Erickson v. Baxter Healthcare, Inc.
151 F. Supp. 2d 952 (N.D. Illinois, 2001)
Williams v. Roberts
202 F.R.D. 294 (M.D. Alabama, 2001)

Cite This Page — Counsel Stack

Bluebook (online)
131 F. Supp. 2d 995, 2001 U.S. Dist. LEXIS 1575, 2001 WL 135709, Counsel Stack Legal Research, https://law.counselstack.com/opinion/erickson-v-baxter-healthcare-inc-ilnd-2001.